A randomised control trial of BIC/F/TAF vs DRV/c/F/TAF in context of HIV test-and-treat, BicTnT.
Humans
HIV Infections
/ drug therapy
Male
Female
Adult
Tenofovir
/ therapeutic use
Anti-HIV Agents
/ therapeutic use
Viral Load
/ drug effects
Emtricitabine
/ therapeutic use
HIV-1
/ drug effects
Adenine
/ analogs & derivatives
Piperazines
/ therapeutic use
Heterocyclic Compounds, 3-Ring
/ therapeutic use
Heterocyclic Compounds, 4 or More Rings
/ therapeutic use
Darunavir
/ therapeutic use
Alanine
/ therapeutic use
Treatment Outcome
RNA, Viral
Sulfonamides
/ therapeutic use
Middle Aged
Cobicistat
/ therapeutic use
United Kingdom
Drug Combinations
Amides
Pyridones
BIC/ftc/taf
DRV/c/F/TAF
HIV infection
rapid ART strategy
test-and-treat
Journal
HIV research & clinical practice
ISSN: 2578-7470
Titre abrégé: HIV Res Clin Pract
Pays: England
ID NLM: 101738312
Informations de publication
Date de publication:
Dec 2024
Dec 2024
Historique:
medline:
8
9
2024
pubmed:
8
9
2024
entrez:
8
9
2024
Statut:
ppublish
Résumé
Head-to-head data for bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF; B) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/c/F/TAF; D) are lacking in the context of rapid antiretroviral therapy (ART) initiation. This study, BIC-T&T, evaluates the efficacy and tolerability of B vs D in a UK test-and-treat setting. BIC-T&T was a randomised, open-label, multi-centre, study in which participants initiated ART within 14 days after confirmed HIV-1 diagnosis before baseline laboratory. The primary endpoint is the virological response (HIV RNA < 50copies/mL) at week 12 by time-weighted average change in log 36 participants were randomised: 94% were male, 53% white; mean (SD) age was 35 years (11.8). Baseline mean (±SD) log In this first head-to-head study in the context of ART initiation, HIV RNA decline from baseline to week 12 was significantly more rapid for BIC/F/TAF compared with DRV/c/F/TAF.
Sections du résumé
BACKGROUND
UNASSIGNED
Head-to-head data for bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF; B) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/c/F/TAF; D) are lacking in the context of rapid antiretroviral therapy (ART) initiation. This study, BIC-T&T, evaluates the efficacy and tolerability of B vs D in a UK test-and-treat setting.
SETTING
UNASSIGNED
BIC-T&T was a randomised, open-label, multi-centre, study in which participants initiated ART within 14 days after confirmed HIV-1 diagnosis before baseline laboratory.
METHODS
UNASSIGNED
The primary endpoint is the virological response (HIV RNA < 50copies/mL) at week 12 by time-weighted average change in log
RESULTS
UNASSIGNED
36 participants were randomised: 94% were male, 53% white; mean (SD) age was 35 years (11.8). Baseline mean (±SD) log
CONCLUSION
UNASSIGNED
In this first head-to-head study in the context of ART initiation, HIV RNA decline from baseline to week 12 was significantly more rapid for BIC/F/TAF compared with DRV/c/F/TAF.
Identifiants
pubmed: 39244669
doi: 10.1080/25787489.2024.2400453
doi:
Substances chimiques
Tenofovir
99YXE507IL
Anti-HIV Agents
0
Emtricitabine
G70B4ETF4S
Adenine
JAC85A2161
Piperazines
0
Heterocyclic Compounds, 3-Ring
0
Heterocyclic Compounds, 4 or More Rings
0
bictegravir
8GB79LOJ07
Darunavir
YO603Y8113
Alanine
OF5P57N2ZX
RNA, Viral
0
Sulfonamides
0
Cobicistat
LW2E03M5PG
Drug Combinations
0
tenofovir alafenamide
EL9943AG5J
Amides
0
Pyridones
0
Types de publication
Journal Article
Randomized Controlled Trial
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM